2-[[5-[[5-[[3-Acetamido-5-[[6-(carboxymethoxymethyl)-5-ethyl-3-(hexanoylamino)-4-hydroxy-2,4,5-trimethyloxan-2-yl]methoxymethyl]-4-hydroxy-6-(hydroxymethyl)-2,4,5-trimethyloxan-2-yl]methoxymethyl]-3-amino-6-(carboxymethoxymethyl)-4-hydroxy-2,4,5-trimethyloxan-2-yl]methoxymethyl]-2-[[5-(hexanoylamino)-4-hydroxy-2-(hydroxymethyl)-6-(methoxymethyl)-3,4,6-trimethyloxan-3-yl]methoxymethyl]-4-hydroxy-6-(hydroxymethyl)-2,4,5-trimethyloxan-3-yl]amino]acetic acid

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: 2-[[5-[[5-[[3-Acetamido-5-[[6-(carboxymethoxymethyl)-5-ethyl-3-(hexanoylamino)-4-hydroxy-2,4,5-trimethyloxan-2-yl]methoxymethyl]-4-hydroxy-6-(hydroxymethyl)-2,4,5-trimethyloxan-2-yl]methoxymethyl]-3-amino-6-(carboxymethoxymethyl)-4-hydroxy-2,4,5-trimethyloxan-2-yl]methoxymethyl]-2-[[5-(hexanoylamino)-4-hydroxy-2-(hydroxymethyl)-6-(methoxymethyl)-3,4,6-trimethyloxan-3-yl]methoxymethyl]-4-hydroxy-6-(hydroxymethyl)-2,4,5-trimethyloxan-3-yl]amino]acetic acid
• 英文别名: 2-[[5-[[5-[[3-acetamido-5-[[6-(carboxymethoxymethyl)-5-ethyl-3-(hexanoylamino)-4-hydroxy-2,4,5-trimethyloxan-2-yl]methoxymethyl]-4-hydroxy-6-(hydroxymethyl)-2,4,5-trimethyloxan-2-yl]methoxymethyl]-3-amino-6-(carboxymethoxymethyl)-4-hydroxy-2,4,5-trimethyloxan-2-yl]methoxymethyl]-2-[[5-(hexanoylamino)-4-hydroxy-2-(hydroxymethyl)-6-(methoxymethyl)-3,4,6-trimethyloxan-3-yl]methoxymethyl]-4-hydroxy-6-(hydroxymethyl)-2,4,5-trimethyloxan-3-yl]amino]acetic acid
• 化学式: C₇₇H₁₃₉N₅O₂₉
• 分子量: 1598.9
• InChiKey: LBHSHNAEFCNECW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -6.2
• 重原子数：
  111
• 可旋转键数：
  44
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.92
• 拓扑面积：
  510
• 氢给体数：
  16
• 氢受体数：
  31

文献信息

• DRUG COMPOSITION AND METHOD FOR PREPARING THE SAME
  申请人：National Chiao Tung University

  公开号：US20170027877A1

  公开（公告）日：2017-02-02

  The present invention provides a method for preparing a drug composition, which includes steps of dispersing an amphiphilic chitosan derivative, at least a hydrophobic drug, and at least a hydrophilic drug into a solvent to form a mixture solution, and the pH value of the mixture solution is adjusted to a range without precipitating the hydrophilic drug(s) and the hydrophobic drug(s), wherein the amphiphilic chitosan derivative is modified by a plurality of hydrophilic group(s) and a plurality of hydrophobic group(s); and after stirring the mixture solution for at least 12 hours, receiving the drug composition when the pH value of the mixture solution is between pH 6 to 7. The hydrophilic drug(s) and the hydrophobic drug(s) are encapsulated simultaneously by one-pot synthesis, and the protein could be modified by one-pot synthesis to provide a drug composition with multiple functions.